Sansure Biotech Inc (688289) — Capital Reinvestment Ratio

Latest as of September 2025: 1.06x

Sansure Biotech Inc (688289) has a Capital Reinvestment Ratio of 1.06x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥59.72 Million) in capital expenditures (CN¥63.08 Million). Check 688289 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

1.06x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥59.72 Million
CNY

Capital Expenditures

CN¥63.08 Million
CNY

Data as of

Sep 2025
Most recent filing

Sansure Biotech Inc Capital Reinvestment Ratio (2018–2025)

This chart tracks Sansure Biotech Inc's Capital Reinvestment Ratio across 8 annual periods. For the full cash flow conversion analysis, see 688289 cash flow metrics.

Annual Capital Reinvestment Ratio for Sansure Biotech Inc (2018–2025)

Year-by-year Capital Reinvestment Ratio for Sansure Biotech Inc from 2018 to 2025. See Sansure Biotech Inc (688289) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 2.01x CN¥183.96 Million CN¥369.77 Million ▲ +31.0%
2024 1.53x CN¥274.45 Million CN¥421.10 Million ▼ -55.8%
2023 3.47x CN¥112.82 Million CN¥391.35 Million ▲ +1488.4%
2022 0.22x CN¥2.56 Billion CN¥558.83 Million ▲ +9.9%
2021 0.20x CN¥1.88 Billion CN¥372.86 Million ▲ +383.0%
2020 0.04x CN¥2.64 Billion CN¥108.67 Million ▼ -97.3%
2019 1.52x CN¥22.41 Million CN¥34.14 Million ▼ -53.4%
2018 3.27x CN¥10.07 Million CN¥32.90 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow